Waltham, Massachusetts-based Thermo Fisher Scientific Inc. (TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. The company has a market cap of $217.5 billion and operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Shares of Thermo Fisher have slightly lagged behind the broader market over the past year, surging 20.3% compared to the S&P 500 Index’s ($SPX) 20.4% surge. Moreover, in 2026, the stock has grown by nearly 1.5%, also underperforming SPX’s 13.7% gain.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Zooming in further, the State Street Healthcare Select Sector SPDR ETF (XLV) has risen 22.4% over the past year, outperforming the stock. In 2026, XLV has surged 7.7% and outpaced the stock.
www.barchart.com Analysts have deemed TMO to be a stock to be skeptical of, instead of being quite profitable due to its mixed fundamentals. The stock has experienced an absence of organic revenue growth over the past two years. Additionally, its efficiency has decreased over the last five years, as showcased by its declining operating margin over the years. Moreover, TMO’s EPS fell by 1.4% annually over the last five years while its revenue saw growth, indicating less-than-profitable sales values.
For the current year, which ends in December, analysts expect TMO’s EPS to rise 9.8% to $25.12 on a diluted basis. The company surpassed the consensus estimate in each of the last four quarters.
Among the 26 analysts covering TMO stock, the consensus is a “Strong Buy.” That’s based on 20 “Strong Buy” ratings, one “Moderate Buy,” and five “Holds.”
www.barchart.com The configuration has remained the same over the past months.
On July 29, J.P. Morgan analyst Casey Woodring maintained a “Buy” rating for TMO stock and raised its price target from $600 to $690.
TMO’s mean price target of $635.08 offers an upside of 7.4% compared to the current market price. Its Street-high target of $750 implies a robust 26.8% upside from current levels.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Meta Takes a Major New Approach to AI. What It Means for Investors. Why There Might Be a Case for Taiwan Semiconductor Stock at $450 in September LinkedIn Just Cut Its Israel R&D Team. Microsoft Stock Investors Shouldn’t Sweat the Layoffs. Alphabet Stock Has Attractive Short-Put Yields As GOOGL Stock Treads Water